Want to see IN:PFIZER full AI Analyst Report?

PFIZER LIMITED (PFIZER) Price & Analysis

124 Followers

PFIZER Stock Chart & Stats

₹4617.70

₹24.30(0.52%)

At close: Jul 28 4:00 PM EDT

₹4617.70

₹24.30(0.52%)

Day’s Range― - ―

52-Week Range₹4,361.00 - ₹5,761.00

Previous CloseN/A

Volume14.93K

Average Volume (3M)2.39K

Market Cap

₹225.14B

Enterprise Value₹185.51K

Total Cash (Recent Filing)₹30.88B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)31.0

Beta0.57

Next Earnings

Nov 03, 2026

EPS Estimate

42.9

Next Dividend Ex-DateN/A

Dividend Yield1.51%

Share Statistics

EPS (TTM)160.69

Shares Outstanding45,747,730

10 Day Avg. Volume3,328

30 Day Avg. Volume2,388

Financial Highlights & Ratios

PEG Ratio-5.08

Price to Book (P/B)5.14

Price to Sales (P/S)8.57

P/FCF Ratio19.31

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)183.6

Revenue Forecast (FY)₹27.22B

Bulls Say, Bears Say

Bulls Say

Very Low LeverageExceptionally low leverage reduces financial risk and interest burden, giving Pfizer Limited greater resilience through industry cycles and flexibility to support research, commercialization, operating needs, and potential capital returns.

Strong ProfitabilitySustained high net and operating profitability indicates a durable earnings base for a large pharmaceutical business, supporting reinvestment in products and operations while providing a buffer against pricing and cost pressures.

Improved Cash GenerationRecent cash conversion suggests reported earnings are being supported by operating cash generation, strengthening the company’s capacity to fund working capital, commercialization, research support, and other long-term business requirements.

Bears Say

Uneven Revenue TrajectoryThe pattern of declines followed by recovery points to an uneven top-line trajectory, which may reflect product, market-access, or portfolio fluctuations and makes sustained revenue expansion less certain over the medium term.

Gross-margin PressureA meaningful gross-margin decline can weaken the economics of the product portfolio if it persists, potentially reflecting pricing, mix, manufacturing, or input-cost pressure and limiting the sustainability of future operating profitability.

Cash-flow VolatilityThe earlier shortfall in operating cash conversion shows that earnings quality and liquidity generation have not been consistently stable across periods, creating a medium-term risk if the recent improvement does not persist.

PFIZER LIMITED News

Pfizer Limited Sets July 28 Virtual AGM, Proposes Rs 75 Final Dividend

An update from PFIZER LIMITED ( ($IN:PFIZER) ) is now available. Pfizer Limited has scheduled its 75th Annual...

2M ago

Pfizer Limited Clears FY26 Results, Recommends Rs 75 Dividend and Sets AGM Date

PFIZER LIMITED ( ($IN:PFIZER) ) just unveiled an update. Pfizer Limited’s board has approved the audited financial results...

3M ago

Pfizer Limited Sets Record Date for Substantial Final Dividend Payout

PFIZER LIMITED ( ($IN:PFIZER) ) has issued an announcement. Pfizer Limited’s board has recommended a final dividend of...

3M ago

Pfizer Limited Rectifies Technical Error in XBRL Financial Filing

PFIZER LIMITED ( ($IN:PFIZER) ) just unveiled an update. Pfizer Limited has clarified a technical issue related to...

4M ago

Pfizer Limited Opens Special Window for Dematerialisation of Physical Shares

PFIZER LIMITED ( ($IN:PFIZER) ) has shared an announcement. Pfizer Limited has notified the stock exchanges that it...

5M ago

Exchange Seeks Clarification from Pfizer Limited on Q2 FY2025 Financial Results

PFIZER LIMITED ( ($IN:PFIZER) ) has issued an announcement. The stock exchange has requested clarification from Pfizer Limited...

8M ago

PFIZER FAQ

What was PFIZER LIMITED’s price range in the past 12 months?

PFIZER LIMITED lowest stock price was ₹4361.00 and its highest was ₹5761.00 in the past 12 months.

What is PFIZER LIMITED’s market cap?

PFIZER LIMITED’s market cap is ₹225.14B.

When is PFIZER LIMITED’s upcoming earnings report date?

PFIZER LIMITED’s upcoming earnings report date is Nov 03, 2026 which is in 72 days.

How were PFIZER LIMITED’s earnings last quarter?

PFIZER LIMITED released its earnings results on Jul 28, 2026. The company reported ₹44.7 earnings per share for the quarter, missing the consensus estimate of ₹45.2 by -₹0.5.

Is PFIZER LIMITED overvalued?

According to Wall Street analysts PFIZER LIMITED’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does PFIZER LIMITED pay dividends?

PFIZER LIMITED pays a Notavailable dividend of ₹75 which represents an annual dividend yield of 1.51%. See more information on PFIZER LIMITED dividends here

What is PFIZER LIMITED’s EPS estimate?

PFIZER LIMITED’s EPS estimate is 42.9.

How many shares outstanding does PFIZER LIMITED have?

PFIZER LIMITED has 45,747,730 shares outstanding.

What happened to PFIZER LIMITED’s price movement after its last earnings report?

PFIZER LIMITED reported an EPS of ₹44.7 in its last earnings report, missing expectations of ₹45.2. Following the earnings report the stock price went up 0.329%.

Which hedge fund is a major shareholder of PFIZER LIMITED?

Currently, no hedge funds are holding shares in IN:PFIZER

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PFIZER LIMITED

Pfizer Limited operates as a pharmaceutical company, engaged in the development, promotion, sale, and international export of medicinal products. Its diverse product range addresses numerous therapeutic needs, such as those related to the neuro/central nervous system, hormonal balance, cardiovascular health, hemophilia, infectious diseases, gynecology, pain relief, orthopedic conditions, oncology, urology, parasitic infections, gastrointestinal disorders, vaccinations, respiratory ailments, and nutritional supplements. The company markets its offerings predominantly under various brand names through an extensive network of independent distributors. Established in 1950, its corporate headquarters are situated in Mumbai, India.